Lilian Chow Closely-held Cerecin appointed Lilian Chow as VP of clinical operations and regulatory affairs, responsible for leading Cerecin’s upcoming Phase 3 study of tricaprilin for the treatment of Alzheimer’s...
BriaCell Therapeutics (TSXV:BCT; OTCQB:BCTXF)initiated dosing in a Phase 1/2a clinical study of its lead product candidate, Bria-IMT, in combination with Incyte’s INCMGA00012 and epacadostat in patients with advanced...
BTIG initiated coverage of Sutro Biopharma (NASDAQ:STRO) with a “buy” rating and $19 price target. The stock closed at $8.43 on Oct. 4. Sutro exploits rapid DNA-to-protein cycle times of cell free biosynthesis to...
SVB Leerink raised its price target for AMAG Pharmaceuticals (NASDAQ:AMAG) to $14 from $9 ahead of an FDA advisory committee meeting on Oct. 29. The stock closed at $11.50 on Oct. 4. “Based on our MEDACorp survey of 50...
Hepion Pharmaceuticals (NASDAQ:HEPA) promoted Daren Ure, Daniel Trepanier and Patrick Mayo to the new roles of CSO; SVP of drug development; and SVP of clinical pharmacology, respectively, to further advance the...
H.C. Wainwright launched coverage of Fulcrum Therapeutics (NASDAQ:FULC) with a “buy” rating and $21 price target. The stock closed at $6.59 on Oct. 2. Fulcrum’s lead program, losmapimod, a p38 alpha/beta MAP kinase...
H.C. Wainwright initiated coverage of PhaseBio Pharmaceuticals (NASDAQ:PHAS) with a “buy” rating and $18 price target. The stock closed at $4.03 on Oct. 2. PhaseBio’s Phase 2 candidate, PB2452, which is licensed from...
Ra Pharmaceuticals (NASDAQ:RARX) dosed the first patient in its RAISE study, a pivotal Phase 3 clinical trial evaluating zilucoplan for the treatment of generalized myasthenia gravis (gMG). gMG is a chronic autoimmune...
ArQule (NASDAQ:ARQL) dosed the first patient in its MOSAIC trial evaluating miransertib for the treatment of Proteus syndrome (PS) and phosphoinositide 3 kinase (PIK3CA)-related overgrowth spectrum disorders (PROS). PS...
Following a Type C FDA meeting, Savara (NASDAQ:SVRA) reported that the agency did not recommend it submit a biologics license application (BLA) for Molgradex for the treatment of autoimmune pulmonary alveolar...
Closely-held LumiThera enrolled the first patient in its multi-center U.S. clinical trial in patients with dry age-related macular degeneration (AMD). The study, called LIGHTSITE III, will evaluate LumiThera’s Valeda...
The FDA has cleared Ziopharm Oncology’s (NASDAQ:ZIOP) IND for CD19-specific CAR-T for the treatment of relapsed CD19+ leukemias and lymphomas. The drug candidate is based on Ziopharm’s non-viral T cell modification...